Restricted accessResearch articleFirst published online 2018-12
Further Support for the Involvement of Genetic Variants Related to the Serotonergic Pathway in the Antidepressant Response in Children and Adolescents After a 12-Month Follow-Up: Impact of the HTR2A rs7997012 Polymorphism
Fluoxetine is an effective and well-tolerated pharmacological treatment for children and adolescents with major depressive disorder (MDD). However, a high percentage of patients do not respond. There is a substantial genetic contribution to this variable clinical outcome. Based on previous genetic results of our group and given the lack of pharmacogenetics studies of antidepressant response with a long follow-up period, we evaluated the influence of single nucleotide polymorphisms (SNPs) in genes related to the serotonergic pathway on remission and recovery in children and adolescents diagnosed with MDD after 12 months of initiating fluoxetine treatment.
Methods:
The assessment was performed in 46 patients. All of them were visited at least once a month during the 12-month follow-up. Psychiatrists interviewed patients and their parents to explore clinical improvement. A total of 75 genotyped SNPs in 10 candidate genes were included in the genetic association analysis with remission and recovery. Bonferroni correction for multiple testing was applied to avoid false positive results.
Results:
The HTR2A rs7997012 SNP was significantly associated after Bonferroni correction with clinical improvement. Particularly, the homozygotes for the major allele (GG) showed the highest percentage of remitters and the highest score reductions on the Clinical Global Impressions-Severity (CGI-S) scale. Moreover, although the results were on the border of statistical significance, the GG homozygotes also tended to experience fewer readmissions during the follow-up period
Conclusions:
These results provide more evidence of the involvement of genetic variants related to the serotonergic pathway in the antidepressant response. Studies with larger cohorts are needed to integrate all relevant variants into clinical predictors of antidepressant response.
Get full access to this article
View all access options for this article.
References
1.
American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, 4th ed. Washington DC: American Psychiatric Press; 1994.
BachmannCJ, AagaardL, BurcuM, GlaeskeG, KalverdijkLJ, PetersenI, Schuiling-VeningaCC, WijlaarsL, ZitoJM, HoffmannF: Trends and patterns of antidepressant use in children and adolescents from five western countries, 2005–2012. Eur Neuropsychopharmacol, 26:411–419, 2016.
4.
BelzeauxR, LinR, JuC, ChayMA, FioriLM, LutzPE, TureckiG: Transcriptomic and epigenomic biomarkers of antidepressant response. J Affect Disord, 8:pii: S0165-0327(17)30940-0, 2017.
5.
BlázquezA, GassóP, MasS, PlanaMT, LafuenteA, LázaroL: One-year follow-up of children and adolescents with major depressive disorder: Relationship between clinical variables and Abcb1 gene polymorphisms. Pharmacopsychiatry, 49:248–253, 2016.
6.
BlázquezA, MasS, PlanaMT, GassóP, MéndezI, TorraM, ArnaizJA, LafuenteA, LázaroL: Plasma fluoxetine concentrations and clinical improvement in an adolescent sample diagnosed with major depressive disorder, obsessive-compulsive disorder, or generalized anxiety disorder. J Clin Psychopharmacol, 34:318–326, 2014.
7.
BlázquezA, MasS, PlanaMT, LafuenteA, LázaroL: Fluoxetine pharmacogenetics in child and adult populations. Eur Child Adolesc Psychiatry, 21:599–610, 2012.
8.
CostelloEJ, FoleyDL, AngoldA: 10-year research update review: The epidemiology of child and adolescent psychiatric disorders: II. Developmental epidemiology. J Am Acad Child Adolesc Psychiatry, 45:8–25, 2006.
9.
EmslieGJ, HeiligensteinJH, HoogSL, WagnerKD, FindlingRL, McCrackenJT, NilssonME, JacobsonJG: Fluoxetine treatment for prevention of relapse of depression in children and adolescents: A doubleblind, placebo-controlled study. J Am Acad Child Adolesc Psychiatry, 43:1397–1405, 2004.
10.
FabbriC, CrisafulliC, CalabròM, SpinaE, SerrettiA: Progress and prospects in pharmacogenetics of antidepressant drugs. Expert Opin Drug Metab Toxicol, 12:1157–1168, 2016.
11.
FabbriC, SerrettiA: Pharmacogenetics of major depressive disorder: Top genes and pathways toward clinical applications. Curr Psychiatry Rep, 17:50, 2015.
12.
FakhouryM: Revisiting the serotonin hypothesis: Implications for major depressive disorders. Mol Neurobiol, 53:2778–2786, 2016.
13.
FrankE, PrienRF, JarrettRB, KellerMB, KupferDJ, LavoriPW, RushAJ, WeissmanMM: Conceptualization and rationale for consensus definitions of terms in major depressive disorder. Remission, recovery, relapse, and recurrence. Arch Gen Psychiatry, 48:851–855, 1991.
14.
GassóP, RodríguezN, BlázquezA, MonteagudoA, BolocD, PlanaMT, LafuenteA, LázaroL, ArnaizJA, MasS: Epigenetic and genetic variants in the HTR1B gene and clinical improvement in children and adolescents treated with fluoxetine. Prog Neuropsychopharmacol Biol Psychiatry, 75:28–34, 2017a.
15.
GassóP, RodríguezN, BolocD, BlázquezA, TorresT, GortatA, PlanaMT, LafuenteA, MasS, ArnaizJA, LázaroL: Association of regulatory TPH2 polymorphisms with higher reduction in depressive symptoms in children and adolescents treated with fluoxetine. Prog Neuropsychopharmacol Biol Psychiatry, 77:236–240, 2017b.
16.
GassóP, RodríguezN, MasS, PagerolsM, BlázquezA, PlanaMT, TorraM, LázaroL, LafuenteA: Effect of CYP2D6, CYP2C9 and ABCB1 genotypes on fluoxetine plasma concentrations and clinical improvement in children and adolescent patients. Pharmacogenomics J, 14:457–462, 2014.
17.
GliedS, PineDS: Consequences and correlates of adolescent depression. Arch Pediatr Adolesc Med, 156:1009–1014, 2002.
18.
GonzálezJR, ArmengolL, SoléX, GuinóE, MercaderJM, EstivillX, MorenoV: SNPassoc: An R package to perform whole genome association studies. Bioinformatics, 23:644–645, 2007.
19.
GuyW: ECDEU Assessment Manual for Psychopharmacology, Revised. Bethesda, MD: United States Department of Health, Education, and Welfare, 1976.
20.
HeltonSG, LohoffF: Serotonin pathway polymorphisms and the treatment of major depressive disorder and anxiety disorders. Pharmacogenomics, 16:541–553, 2015.
21.
HetrickS, MerryS, McKenzieJ, SindahlP, ProctorM: Selective serotonin reuptake inhibitors (SSRIs) for depressive disorders in children and adolescents. Cochrane Database Syst Rev, 3:CD004851, 2007.
22.
HorstmannS, BinderEB: Pharmacogenomics of antidepressant drugs. Pharmacol Ther, 124:57–73, 2009.
23.
HorstmannS, LucaeS, MenkeA, HenningsJM, IsingM, RoeskeD, Müller-MyhsokB, HolsboerF, BinderEB: Polymorphisms in GRIK4, HTR2A, and FKBP5 show interactive effects in predicting remission to antidepressant treatment. Neuropsychopharmacology, 35:727–740, 2010.
24.
KatoM, SerrettiA: Review and meta-analysis of antidepressant pharmacogenetic findings in major depressive disorder. Mol Psychiatry, 15:473–500, 2010.
25.
KaufmanJ, BirmaherB, BrentD, RaoU, FlynnC, MoreciP, WilliamsonD, RyanN: Schedule for Affective Disorders and Schizophrenia for School-Age Children-Present and Lifetime Version (K-SADS-PL): Initial reliability and validity data. J Am Acad Child Adolesc Psychiatry, 36:980–988, 1997.
26.
KovacsM: Children's Depression Inventory manual. New York: Multi-Health Systems, 1992.
27.
KratochvilCJ, VitielloB, WalkupJ, EmslieG, WaslickBD, WellerEB, BurkeWJ, MarchJS: Selective serotonin reuptake inhibitors in pediatric depression: Is the balance between benefits and risks favorable?. J Child Adolesc Psychopharmacol, 16:11–24, 2006.
28.
LajeG, CannonDM, AllenAS, KlaverJM, PeckSA, LiuX, ManjiHK, DrevetsWC, McMahonFJ: Genetic variation in HTR2A influences serotonin transporter binding potential as measured using PET and [11C]DASB. Int J Neuropsychopharmacol. 13715–13724, 2010.
29.
LinJY, JiangMY, KanZM, ChuY: Influence of 5-HTR2A genetic polymorphisms on the efficacy of antidepressants in the treatment of major depressive disorder: A meta-analysis. J Affect Disord, 168:430–438, 2014.
30.
LinE, TsaiSJ: Genome-wide microarray analysis of gene expression profiling in major depression and antidepressant therapy. Prog Neuropsychopharmacol Biol Psychiatry, 64:334–340, 2016.
31.
LisowayAJ, ZaiCC, TiwariAK, KennedyJL: DNA methylation and clinical response to antidepressant medication in major depressive disorder: A review and recommendations. Neurosci Lett: pii: S0304-3940(16)31019-9, 2017.
MasS, BlázquezA, RodríguezN, BolocD, LafuenteA, ArnaizJA, LázaroL, GassóP: Pharmacogenetic study focused on fluoxetine pharmacodynamics in children and adolescent patients: Impact of the serotonin pathway. Pharmacogenet Genomics, 26:487–496, 2016.
36.
McMahonFJ, BuervenichS, CharneyD, LipskyR, RushAJ, WilsonAF, SorantAJ, PapanicolaouGJ, LajeG, FavaM, TrivediMH, WisniewskiSR, ManjiH: Variation in the gene encoding the serotonin 2A receptor is associated with outcome of antidepressant treatment. Am J Hum Genet, 78:804–814, 2006.
37.
NiitsuT, FabbriC, BentiniF, SerrettiA: Pharmacogenetics in major depression: A comprehensive meta-analysis. Prog Neuropsychopharmacol Biol Psychiatry, 45:183–194, 2013.
38.
NoroM, AntonijevicI, ForrayC, KasperS, KocabasNA, LecrubierY, LinotteS, MendlewiczJ, MontgomeryS, SnyderL, SoueryD, VerbanckP, ZoharJ, MassatI: 5HT1A and 5HT2A receptor genes in treatment response phenotypes in major depressive disorder. Int Clin Psychopharmacol, 25:228–231, 2010.
ShafferD, GouldMS, BrasicJ, AmbrosiniP, FisherP, BirdH, BirdH, AluwahliaS: A children's global assessment scale (CGAS). Arch Gen Psychiatry, 40:1228–1231, 1983.
41.
SheltonRC, Sanders-BushE, ManierDH, LewisDA: Elevated 5-HT 2A receptors in postmortem prefrontal cortex in major depression is associated with reduced activity of protein kinase A. Neuroscience, 158:1406–1415, 2009.
42.
SinghAB, BousmanCA: Antidepressant pharmacogenetics. Am J Psychiatry, 174:417–418, 2017.
43.
TanseyKE, GuipponiM, HuX, DomeniciE, LewisG, MalafosseA, WendlandJR, LewisCM, McGuffinP, UherR: Contribution of common genetic variants to antidepressant response. Biol Psychiatry, 73:679–682, 2013.
44.
Treatment for Adolescents with Depression Study Team: The treatment for adolescents with depression study (TADS): Outcomes over 1 year of naturalistic follow-up. Am J Psychiatry, 166:1141–1149, 2009.
45.
UlloaRE, OrtizS, HigueraF, NogalesI, FresánA, ApiquianR, CortésJ, ArechavaletaB, FoulliuxC, MartínezP, HernándezL, DomínguezE, de la PeñaF: Interrater reliability of the Spanish version of Schedule for Affective Disorders and Schizophrenia for School-Age Children—Present and Lifetime version (K-SADS-PL). Actas Esp Psiquiatr, 34:36–40, 2006.
46.
XiaL, YaoS: The involvement of genes in adolescent depression: A systematic review. Front Behav Neurosci, 9:329, 2015.
47.
ZhaoX, SunL, SunYH, RenC, ChenJ, WuZQ, JiangYH, LvXL: Association of HTR2A T102C and A-1438G polymorphisms with susceptibility to major depressive disorder: A meta-analysis. Neurol Sci, 35:1857–1866, 2014.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
